Therefore, increasing adiponectin production and/or adiponectin signalling are attractive targets for therapeutic interventions for the prevention or treatment of obesity-related derangements in metabolism. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.